23andMe completes $305M asset sale to TTAM Research Institute in bankruptcy

Chrome Holding Co.

Purchase price of $305M cash plus assumption of liabilities; Lemonaid Health excluded business acquired for $2.5M.
Buyer TTAM is an affiliate of co-founder Anne Wojcicki; transaction consummated July 14, 2025.
DIP credit facility with JMB Capital Partners fully repaid and terminated upon closing.
Chapter 11 cases remain pending; distribution of proceeds to shareholders to be disclosed later.
23andMe continues operating as part of TTAM, offering DNA testing and research services.

item 1.02item 2.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.